Obstetrics and gynecology
-
Obstetrics and gynecology · Aug 2002
Randomized Controlled Trial Comparative Study Clinical TrialValdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea.
To compare the efficacy of the cyclooxygenase (COX)-2-specific inhibitor valdecoxib with naproxen sodium in treating menstrual pain associated with primary dysmenorrhea. ⋯ Both valdecoxib 20- and 40-mg doses were effective and well tolerated for the treatment of primary dysmenorrhea. Valdecoxib 20 mg and 40 mg demonstrate analgesic efficacy, based on onset, magnitude, and duration of analgesia that is similar to naproxen sodium, making it a potential choice for treating women with primary dysmenorrhea.